Toward the Broad Adoption of 3D Tumor Models in the Cancer Drug Pipeline
The DOI matches its Crossref record; 146 of the 155 references it cites were found in a registry or an index.
Abstract
Despite a cost of approximately $1 billion to develop a new cancer drug, about 90% of drugs that enter clinical trials fail. A tremendous opportunity exists to streamline the drug selection and testing process, and innovative approaches promise to reduce the burdensome cost of health care for those suffering from cancer. There is great potential for 3D models of human tumors to complement more traditional testing methods; however, the shift from 2D to 3D assays at early stages of the drug discovery and development process is far from widely accepted. 3D platforms range from simple tumor spheroids to more complex microfluidic hydrogels that better mimic the tumor microenvironment. While several companies have developed and patented advanced high-throughput 3D platforms for drug screening, their cost and complexity have limited their adoption as an industry standard. In this review, we will highlight the various tumor platforms that have been developed, emphasizing the approaches that have successfully led to commercial products. We will then consider potential directions toward more relevant tumor models, advantages of the adoption of such platforms within the drug development and screening process, and new opportunities in personalized medicine that such platforms will uniquely enable.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Yet, challenges remain before microfluidic assays can be routinely used in the clinic [82, 83] (Outstanding Question Box) [84].”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [82]
Citations
Cites
Lutolf, M. P., & Hubbell, J. A. (2005) · Nature Biotechnology · doi:10.1038/nbt1055 · Cited by 4,551
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Collagen Structure and Stability
Shoulders, M. D., & Raines, R. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.032207.120833 · Cited by 3,923
Bhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
The third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817
Hydrogels as extracellular matrix mimics for 3D cell culture
Tibbitt, M. W., & Anseth, K. S. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22361 · Cited by 2,727
Breast cancer metastasis: markers and models
Weigelt, B., Peterse, J. L., & van't Veer, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1670 · Cited by 2,232
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Research works printed but not linked: 7
- Gevaert M., 2012, Natl. Acad. Eng., 42
- Sutherland R. M., 1971, J. Natl. Cancer Inst., 46, 113
- Zohrabian V. M., 2009, Anticancer Res., 29, 119
- Kosaki R., 1999, Cancer Res., 59, 1141
- Frankel A., 1997, Cancer Res., 57, 2388
- Koutsiaris A. G., 2006, Biorheology, 44, 375
- Takagi A., 2007, Anticancer Res., 27, 45
Cited by
3D tumor spheroids: an overview on the tools and techniques used for their analysis
Costa, E. C., Moreira, A. F., de Melo-Diogo, D., Gaspar, V. M., Carvalho, M. P., & Correia, I. J. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.11.002 · Cited by 929
Design of spherically structured 3D in vitro tumor models -Advances and prospects
Ferreira, L. P., Gaspar, V. M., & Mano, J. F. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.05.034 · Cited by 249
“tumors, could improve the efficacy of anti-cancer drug discovery and biological performance screening [1].”
BackgroundMicrofluidics: A New Tool for Modeling Cancer–Immune Interactions
Boussommier-Calleja, A., Li, R., Chen, M. B., Wong, S. C., & Kamm, R. D. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2015.12.003 · Cited by 224
“Yet, challenges remain before microfluidic assays can be routinely used in the clinic [82, 83] (Outstanding Question Box) [84].”
MethodLazzari, G., Couvreur, P., & Mura, S. (2017) · Polymer Chemistry · doi:10.1039/c7py00559h · Cited by 200
High-Content Monitoring of Drug Effects in a 3D Spheroid Model
Mittler, F., Obeïd, P., Rulina, A. V., Haguet, V., Gidrol, X., & Balakirev, M. Y. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00293 · Cited by 194
Metadata
- Authors
- Cox, M. C., Reese, L. M., Bickford, L. R., & Verbridge, S. S.
- Affiliations
- Virginia Tech - Wake Forest University School of Biomedical Engineering & Sciences (US)
- Corresponding author
- Verbridge, Scott S.
- Venue
- ACS Biomaterials Science & Engineering
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-09-11
- Volume
- 1
- Issue
- 10
- Pages
- 877-894
- ISSN
- 2373-9878 (ISSN-L)
- OpenAlex
- W2471940455
- Cited by
- 80
- References
- 155
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 8 · 2022: 11 · 2021: 9 · 2020: 13 · 2019: 8 · 2018: 10 · 2017: 7 · 2016: 9
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- ACS Biomaterials Science & Engineering (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institute for Critical Technology and Applied Science, Virginia Polytechnic Institute and State University
- College of Engineering, Virginia Polytechnic Institute and State
- National Institute of Biomedical Imaging and Bioengineering (R21EB019123)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Physical Sciences › Materials Science › Biomaterials › Hydrogels: synthesis, properties, applications
- Keywords
- 3D tumor models, anticancer drug discovery, tumor spheroids, tumor microenvironment, high-throughput drug screening, personalized medicine, drug development costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.